Vaxxas
PrivateLast Round
Series D
Aug 25, 2025
Est. Valuation
$805M
Total Funding Raised
$168.59M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Vaxxas operates in Healthcare & Life Sciences and is based in Brisbane. Its latest recorded funding round was a Series D round in August 2025.
Vaxxas is a biotechnology company that develops a needle-free, patch-based vaccine delivery technology designed to improve vaccine performance and stability.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vaxxas Comparables
Compare Vaxxas with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Micron Biomedical | 88% | |
| PharmaJet | 82% | |
| Verndari, Inc. | 82% |
For institutional investors. Book with your work email.
Vaxxas Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 25, 2025 | ||||
| Debt | Aug 25, 2025 | ||||
| VC Round | Dec 5, 2022 | ||||
| Grant | Oct 1, 2022 | ||||
| Grant | May 28, 2020 | ||||
Series B | Apr 1, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vaxxas Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UniQuest Pty Ltd | VC Round |
| The University of Queensland | Series B |
| OneVentures | Series D, Series A, VC Round, Series B |
| CEPI | Grant |
| Queensland Government | Grant |
| HealthCare Ventures | Series A, Series B |
| SPRIM Global Investments | Debt, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 28, 2026
Open roles increased to 14, 2.1x the trailing average.
- Jan 7, 2026
David Peacock appointed as new CEO to lead commercialization.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 24, 2026
Vaxxas is a clinical-stage biotechnology company developing the High-Density Microarray Platform (HD-MAP), a needle-free vaccine delivery technology designed to apply vaccines to the skin through thousands of microscopic projections targeting immune cells beneath the skin surface.
For institutional investors. Book with your work email.
Vaxxas Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vaxxas's valuation, stock price, and market status.
Is Vaxxas a public or private company?
Vaxxas is a private company.
What is the current stock price of Vaxxas?
Vaxxas is a private company, so its shares have no public market price. Caplight tracks Vaxxas's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vaxxas worth (valuation)?
Vaxxas's valuation is estimated at $805.0M based on funding round data.
Can I buy Vaxxas stock?
Vaxxas shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vaxxas's last funding round?
Vaxxas's most recent funding round was Series D on August 25, 2025.
Who are the main investors in Vaxxas?
Key investors in Vaxxas include UniQuest Pty Ltd, OneVentures, SPRIM Global Investments, SPRIM Global Investments.
Will Vaxxas IPO soon?
No public IPO plans have been announced for Vaxxas.
How can I track Vaxxas secondary market activity?
Caplight tracks bids, offers, and trades in Vaxxas's shares on secondary markets.